ACC 317 Managerial Accounting: Assignment 1 Start-up Budgeting

unither2008

ReferenceRitterPharmaceuticals.pdf

Home >Business & Finance homework help >Operations Management homework help >ACC 317 Managerial Accounting: Assignment 1 Start-up Budgeting

Company Information

Ritter Pharmaceuticals Inc (NASDAQ) Symbol:RTTR Headquarters 1880 Century Park East #1000 Los Angeles California - 90067 Phone : 1-310-203-1000 Email:[email protected] Website:www.ritterpharmaceuticals.com Industry Classification: Pharmaceuticals and Biotechnology Business Summary Ritter Pharmaceuticals Inc is engaged in developing therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company was founded on March 29, 2004 by Andrew J. Ritter as Ritter Natural Sciences LLC and later changed to Ritter Pharmaceuticals Inc on September 16, 2008. Its mission is to utilize colonic adaptation to develop therapeutics for the treatment of gastrointestinal diseases. The company’s vision is to reduce the impact of lactose intolerance worldwide. Ritter advances human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The company’s microbiome modifiers change and enhance the microbial populations in the gastrointestinal tract in order to improve the health of individuals suffering from gastrointestinal diseases. Its lead product RP-G28 has the potential to become the first FDA-approved treatment for lactose intolerance. The Company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic and liver disease. Ritter has partnerships with University of Nebraska, Covance Inc, Kolu Pohaku Technologies (KPT), University of British Columbia, etc.

LSA Page 1 of 26 © Life Science Analytics, Inc.2019

Table of Contents Product Glance -------------------------- 3

Products by Therapy Area -------------------------- 4

Product Pipeline/Summary -------------------------- 5

Management Profile -------------------------- 6

Recent News -------------------------- 16

Company Announcemets -------------------------- 16

Deals and Alliances -------------------------- 18

Financials -------------------------- 19

Intellectual Property -------------------------- 21

Product Updates -------------------------- 22

Regulatory -------------------------- 26

LSA Page 2 of 26 © Life Science Analytics, Inc.2019

Product Glance Products By Phase of Development

No. of Projects By Phase of Development

Trial Phase No.of Products

Phase III 1

LSA Page 3 of 26 © Life Science Analytics, Inc.2019

Products by Therapy Area

No.of Products by Therapy Area

Therapy Area No.of Products

Endocrine, Metabolic and Genetic Disorders

Gastroenterology 1 Infectious Diseases 1 Oncology 1

LSA Page 4 of 26 © Life Science Analytics, Inc.2019

Product Pipeline

Product Name Condition Treated Trial Phase Source Partner

RPG28 Fatty Liver III -- -- RPG28 Gastrointestinal Infections III -- -- RPG28 Lactose Intolerance III -- -- RPG28 Metabolic Disorders III -- -- RPG28 Oncology III -- --

LSA Page 5 of 26 © Life Science Analytics, Inc.2019

Management Profile

Ira E. Ritter -- Chairman, Co-Founder and Chief Strategy Officer

Ira E. Ritter has extensive experience creating, building and managing diverse business enterprises. His success has been his ability to take ideas and grow major businesses. He serves as Chairman of Ritter Pharmaceuticals. In addition, he provides corporate management, strategic planning and financial consulting for a wide range of market segments. In the health and beauty sector, Ritter was President and Vice-Chairman of Quality King Inc, the nation’s largest wholesale distributor for health care products with $5 billion in annual revenues (ranked the 18th largest privately held company, Forbes Top 100 List). Simultaneously, he worked as President and Chairman of Rockwood, a business he developed that produced private label HBA products for major national retailers including GNC and K-Mart. In the entertainment sector he served as Chairman of ON-TV, a division of Oak Industries (NYSE Company), where he managed the television division initiating exclusive broadcasts of Los Angeles, Chicago, and New York professional baseball, basketball, and hockey games. During 1980-1985, he produced the first televised home shopping program and directed development of the largest “pay-per-view” channel system for its time. In the personal services market, Ritter grew a people-to-people business, Elite Personal Search and Lifemates personal matchmaking service, in the U.S. and Canada. In the finance field, He served on the board of directors for the Martin Lawrence Art Galleries (NYSE Company). During his 20 years as a publisher, he produced monthly national consumer magazines including Playgirl. and released books that included It’s OK to Say No children's series and Patti Regan Davis’ Homefront. Ritter also has a long history of public service that includes appointments by three Governors to several State of California Commissions, including eight years served as Commissioner on the California Prison Industry Authority. In 1981, Ritter was honored with the City of Hope’s Man of the Year award.

Andrew J. Ritter -- Chief Executive Officer, Co-Founder, President, Director and Corporate Secretary

Andrew J. Ritter co-founded Ritter Pharmaceuticals, Inc., upon his personal affliction with lactose intolerance and spearheaded a global team of cross-functional, clinical, manufacturing, and regulatory experts to design and develop its first novel therapeutic called, RP-G28. This product has been successfully tested in a Phase 2a trial and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance. The company was originally launched out of Ritter Naturals Sciences, a direct-to-consumer healthcare marketing company, founded by Ritter in 2004, which developed and commercialized digestive healthcare products: Lactagen®, Health Essentials™ and Better Digestion™. Ritter holds six patents and over fifteen additional international patents are pending. In addition, he has co-published articles in the following journals: Nutrition Journal, Gastroenterology, and Food Technology. He has also given presentations at major healthcare and medical conferences such as Digestive Disease Week, among others. Since 2010, he has also acted as Managing Partner of Stonehenge Partners, a private investment fund, which provides working capital and executive leadership to a variety of businesses and industries including, real estate, technology, biotechnology, entertainment and service businesses. In addition, he is a guest lecturer of entrepreneurship at various graduate and undergraduate academic institutions throughout Los Angeles including: University of Southern California Marshall School of Business, University of California at Los Angeles Anderson School of Business, and Pepperdine University Graziadio School of Business and Management. Ritter has been an active leader in his community, including being appointed as a Los Angeles City Commissioner to the Commission for Children, Youth and Their Families from 2000-2002 (the youngest appointed Commissioner in Los Angeles history). Ritter holds a Bachelor of Arts Degree in Political Science and a minor in Business from the University of Southern California and was a member of the 2002 Pac-10 Champion baseball team. In addition, Ritter received his MBA from The Wharton School, University of Pennsylvania.

Samuel O. Lynn -- Chief Financial Officer

Samuel O. Lynn has over 25 years of financial accounting experience, serving in senior leadership roles within public accounting and banking industries. In addition, Mr. Lynn is currently a Managing Partner of Chord Advisors, LLC. From 2007 to 2014, Mr. Lynn was the Americas Director of Accounting Policy for Goldman Sachs Group, Inc. Mr. Lynn held a similar position with UBS AG from 2005 to 2007. From 1996 to 2005 Mr. Lynn was an audit professional with KPMG LLP, last serving as an audit partner in the firm’s U.S. national office. While at KPMG, Mr. Lynn also served a two-year fellowship at the Financial Accounting Standards Board. Prior to joining KPMG in 1996, Mr. Lynn was an audit manager with Ernst & Young in their Houston,Texas office. Mr. Lynn earned a Bachelor of Accountancy from the University of Oklahoma and is a CPA in New York State.

Bryan Jones -- Team Member - Business Development

LSA Page 6 of 26 © Life Science Analytics, Inc.2019

Mr. Jones has over 20 years of experience in a variety of roles at the interface between science and business. He has a broad therapeutic background in both biological and small molecule drugs and his positions have included work in business development, fund raising, operations, drug development, and licensing. Prior to joining Ritter Pharma, Mr. Jones worked as Chief Operating Officer at Sherrington Pharmaceuticals. In other positions, Mr. Jones has worked on clinical development programs, strategy and operations for startups, and in- licensing and out-licensing programs. Mr. Jones graduated from the University of Washington with a Ph.D. in Genetics and from Iowa State University with a B.S. in Biology/Biochemistry.

Larry I. Good -- Chief Medical Officer

Dr. Good is a board certified gastroenterologist who has been practicing medicine for over 30 years. He is a Fellow of the American College of Gastroenterology and has served as the Chief Physician in Gastroenterology at South Nassau Communities Hospital and Lydia E. Hall Hospital in New York. Dr. Good is nationally recognized for his clinical experience with clostridium difficile and has conducted extensive clinical research in many fields including biliary lipid metabolism, irritable bowel syndrome, and inflammatory bowel disease. He has published numerous abstracts and articles in various journals such as Gastroenterology and the American Journal of Gastroenterology. Additionally, he has over 20 years of experience serving on advisory boards for major pharmaceutical companies primarily focused on providing input towards the development of gastrointestinal treatments, including most notably rifaximin. Dr. Good received his M.D. from the Medical University of South Carolina, served his residency there, and was Chief Resident in Medicine. He was a Fellow in Gastroenterology at the University of Pennsylvania.

Robert Tidwell -- Chief Business Officer

Mr. Tidwell has over 30 years of biotechnology and pharmaceutical industry experience in various business development and marketing positions. Prior to joining Ritter, Mr. Tidwell spent nine years as a Senior Vice President of Corporate Development at Cell Genesys. Before his position at Cell Genesys, Mr. Tidwell was Vice President of Business Development at Calydon, Inc. Other companies where Mr. Tidwell has worked include biopharmaceutical firms such as Scios, Genetics Institute, and Eli Lilly. He holds an M.B.A. from The Ohio State Graduate School of Business and a Bachelor of Pharmacy from The Ohio State School of Pharmacy.

AnnKatrin Petersen-Jappelli -- Chief Medical Officer

AnnKatrin Petersen-Jappelli has more than 25 years of drug development experience. She has worked extensively on diverse therapeutic areas for global studies, notably Gastroenterology, HIV-AIDS, Rheumatoid Arthritis, Transplant Medicine, Oncology and Infectious Diseases. Besides her extensive regulatory, medical and scientific knowledge, she has built international clinical research teams that were instrumental in the conduct of several Phase 2 and registration Phase 3 studies for groundbreaking HIV/AIDS treatments. She has worked for several small to mid-size biotech companies, including Agouron, Migenix, and Santarus. This included pivotal drug trials in infectious diseases and gastrointestistinal disorders for HIV, HCV, and enteric pathogens. Previously Dr. Petersen was the Director of Infectious Diseases at Pfizer, Project Leader for pancreatitis clinical research at Sandoz (Novartis) and previously Medical Monitor for the SandImmune and Sandostatin products. Dr. Petersen studied Medicine and Economics at the University of Lausanne, Switzerland.

John W. Beck -- Chief Financial Officer,Contact Person-Investor Relation

John Beck joins Ritter Pharmaceuticals with over 25 years of experience in leadership roles across finance, accounting and compliance, capital markets, fundraising, mergers and acquisitions and commercial operations in life sciences and high technologies companies. Before joining Ardea, Mr. Beck spent 10 years with Metabasis Therapeutics Inc., as a co-founder and chief financial officer. Prior to joining Metabasis, Mr. Beck served as finance director at Neurocrine Biosciences, Inc. from 1994 to 1998, where he played an important role in that company’s IPO. Mr. Beck currently serves on the boards of advisors of August Therapeutics, Inc. in San Diego, California and Pinnacle Medical Holdings, LLC, in Denver Colorado. Mr. Beck holds a Bachelor’s Degree in Accounting from the University of Washington, Seattle as well as a degree in Theology from a Seattle-area seminary.

Sharron Gargosky -- Vice President, Clinical Operation

Sharron Gargosky 25 years of global clinical development and operational experience. Experience in the field of pharmaceutical and biologic development having managed international programs from early research phase through the U.S Food & Drug Administration approval process.

LSA Page 7 of 26 © Life Science Analytics, Inc.2019

Jennifer Timmerman -- Senior Director, Regulatory Affairs

Jeff Garwin -- Chief Medical Officer

Dr. Garwin has over 30 years experience and expertise in a broad spectrum of medical affairs, regulatory affairs, and clinical development. In his previous position, Dr. Garwin was a Director of Medical Affairs, in Respiratory Health and a Medical Director of the Venture Group for GSK Consumer Healthcare. In this position, he supported R&D and commercial efforts including new product conceptualization and assisted in evaluating in-license or acquisition candidates. Dr. Garwin also developed clinical development plans for four anticipated projects and coordinated clinical development with regulatory, commercial, and new product development requirements. Lastly, he developed and supervised one Phase 1 PK/PD study as well as prepared clinical portions of FDA submissions. Before his position with GSK Consumer Healthcare, Dr. Garwin was a Director of Clinical Development and Medical Affairs at Solvay Pharmaceuticals. In this position, he managed clinical development of Men’s Health products globally, including the marketed product AndroGel 1% that achieved US sales exceeding $500 million in 2009. Supervised and approved writing of Clinical Study Reports. Dr. Garwin also developed and executed strategies for presentation of clinical information in FDA briefing documents and eCTD submissions. He graduated with a PhD in Molecular Biophysics and Biochemistry from Yale University, a MD from Yale University, and a BS in Chemistry from Stanford University.

Ellen Mochizuki -- Principal Financial and Accounting Officer

Jeffrey Benjamin -- Vice President, Finance and Contact Person, Investor and Media Relations

Jeffrey Benjamin has over 25 years of experience in accounting and finance. Before joining Ritter Pharmaceuticals, Inc., Benjamin has consulted or worked for a diverse group of public and private Companies in financial services, technology, construction, managed services, retail, wholesale distribution and manufacturing. From 2015 to 2017, Benjamin served as Principal Consultant for Tatum where he was responsible for a variety of finance and accounting projects. During his tenure at Ocwen Financial Corporation, Benjamin successfully completed IPO's, negotiated and closed in excess of $1B of one-off term financing transactions. Benjamin began his career in New York City in public accounting and has worked in a variety of finance and accounting functions before to 2013. He holds a Bachelor of Arts Degree in Accounting & Information Systems from C.U.N.Y. Queens College. In addition, Benjamin is licensed in the State of New York as a certified public accountant, though is on inactive status.

Diane J. Plotkin -- Vice President, Clinical Development

Diane J. Plotkin has over 25 years of experience in global clinical drug development, both in large-scale pharmaceutical companies and biotechnology companies. From 2014-2017, Plotkin served as a clinical development consultant providing guidance on various clinical development topics, including strategic program planning, IND filing, CRO selection, clinical study design, conduct and analysis to biotechnology companies. From 2005-2014, Plotkin served as Senior Director of Clinical Development Worldwide for ActivX Biosciences, Inc., a subsidiary of Kyorin Pharmaceuticals, Inc., where she was head of clinical development responsible for evaluating therapeutics for metabolic disorders and providing translational biology guidance for drug discovery. From 1991-2005, Plotkin conducted Phase II-IV trials at Merck Research Laboratories in cardiovascular, endocrine and metabolic therapeutic areas as well as lead teams in clinical development process improvement. He holds a Bachelor of Arts Degree Magna Cum Laude in Biology from Wheaton College, a PhD in Biology from University of Chicago and was a Post-doctoral Fellow in the Department of Biology at Yale University.

Ron Ozur -- Chief Financial Officer

Ron is responsible for all aspects related to finances at Ritter Pharma. For the last ten years, Ron has worked as an independent consultant for numerous companies by assisting with banking, contracts, leases, operations, and strategic planning which include both private and public companies. Prior to starting his own company, Ron worked for KPMG, an international accounting firm, handling both public and private companies, financial reporting, and tax needs as well as numerous IPO’s. He also has thirty-nine years as a part-time professor teaching accounting at a number of colleges in the Los Angeles area. Ron received his Bachelor’s Degree and Master’s Degree in

LSA Page 8 of 26 © Life Science Analytics, Inc.2019

Accounting from the University of Arizona.

Steve Markowitz -- Director

Steve Markowitz s an active private investor, with a particular interest in and passion for applied science. He was a seed investor in Ritter Pharmaceuticals. Prior to private investing, Steve was founding chairman and CEO of MyPoints.com, the membership marketing company that he took public on NASDAQ in 1999. During his tenure, Steve led MyPoints in growing membership to 16 million consumers and annual revenue to $64 million. Before MyPoints, he worked as a securities analyst at Fidelity Investments and as a financial journalist at Dow Jones & Co., where his coverage included pharmaceutical companies.Steve earned his MBA from UC Berkeley’s Haas School of Business and his B.A. in East Asian Languages (high honors), also from UC Berkeley. Steve is a guest lecturer in the Entrepreneurship and New Venture Finance courses at Haas. He was honored as a Richard H. Holton Teaching Fellow in 2009.

Noah J. Doyle -- Director and Member of Nominating and Corporate Governance Committee

Noah Doyle has been an entrepreneur and investor for over 20 years. As an angel investor of Javelin Venture Partners, Noah has supported over a dozen start-ups including Keyhole (Google), Cantametrix (Gracenote), Amae Software (Verint), Nuvon, Aquea Scientific, Emdigo, Magnacash (Yaga), and i-mint India. Doyle directed the enterprise product line for Google’s geospatial products, Google Earth and Google Maps. He managed the Sales and Corporate Development functions at Keyhole, Inc., the venture capital backed company that created the first Web hosted digital earth model and was acquired by Google in 2004. Doyle helped establish the Internet loyalty rewards marketplace as a co-founder of MyPoints.com, the largest Internet loyalty program with over 6 million active members, where he led product management and business development functions from the company’s inception through an initial public offering and subsequent acquisition by United Airlines. Noah was based in Tokyo where he managed overseas sales and marketing for the OEM channel of Matsushita’s (Panasonic) communications equipment subsidiary in Japan. In other roles, he was chairman of the management board of the University of California, Berkeley’s campus bookstore, a $17 million retail operation, and also held product management and operations management roles at IBM/Rational (Pure Atria) and Oracle. Doyle holds M.B.A. and B.A. Economics degrees, as well as certificates in Management of Technology and Global Management from University of California – Berkeley..

William M. Merino -- Director and Member of Compensation, Nominating and Corporate Governance Committee

William M. Merino is a former pharmaceutical senior executive with experience in worldwide drug and device registration, quality assurance, quality control, and drug safety. During his tenure as a senior executive, Merino had extensive interaction, and conducted negotiations, with senior members of the Food and Drug Administration (FDA) and foreign regulatory authorities. He skills also include drug development and the resolution of development issues. Merino served as the Sr. Vice President of Worldwide Regulatory Affairs for Warner Lambert Pharmaceuticals (1987-2000). While at Warner Lambert, he was responsible for the registration and approval of pharmaceuticals products with the FDA and external regulatory authorities. He was also tasked with ensuring quality assurance, quality control, and drug safety. Additionally, during his time at Warner Lambert, Merino served as a member of the Office of the Chairman, where his advice and experience were relied upon in making decisions regarding research direction and drug development. He developed a one year plan to expedite the registration of Lipitor in the US and 20 other countries. Moreover, Merino served as the President of the Regulatory Affairs Committee (RAC) within the Pharmaceutical Manufacturers Association (PMA), where he worked closely with senior FDA officials, as well as Congress. Merino was the Director of International Regulatory Affairs for Alcon Pharmaceuticals (1985-1987), where he was responsible for the registration of devices and pharmaceutical drugs in international countries. He was the Vice President of Worldwide Regulatory Affairs at G.D. Searle & Co., (1975-1985), where he worked with the FDA and regulatory agencies worldwide for the registration and approval of drugs both nationally and internationally. Before that, he was the Director of Regulatory Affairs at Riker Laboratories (1967-1975), where he was in charge of new drug registrations in the US. Merino received his PhD in Pharmacology from Purdue University.

Matthew W. Foehr -- Director, Chairman of Compensation Committee and Member of Audit Committee

Matthew W. Foehr serves as President and Chief Operating Officer at Ligand Pharmaceuticals. He has 20 years of experience in the pharmaceutical industry, having managed global operations and research and development programs. He was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). Following GSK’s $3.6 billion acquisition of Stiefel in 2009, Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. He is a Director on the Board of Viking Therapeutics Inc. Foehr is

LSA Page 9 of 26 © Life Science Analytics, Inc.2019

the author of multiple scientific publications and is named on numerous U.S. patents. He received his Bachelor of Science degree in Biology from Santa Clara University.

Gerald T. Proehl -- Director, Chairman of Nominating and Corporate Governance Committee and Member of Audit Committee

Gerald T. Proehl has served as a director since April 2014. From January 2002 to January 2014, he was the President, Chief Executive Officer and a Director of Santarus, Inc. (“Santarus”), a company that he helped to found in 1999. From March 2000 through December 2001, Proehl was President and Chief Operating Officer of Santarus, and from April 1999 to March 2000, Proehl was Vice President, Marketing and Business Development of Santarus. Proehl helped lead the sale of Santarus to Salix Pharmaceuticals for $2.6 billion in January of 2014. Proehl was with Hoechst Marion Roussel, Inc. (“Hoechst”), a global pharmaceutical company, for 14 years, where he served in various capacities, including Vice President of Global Marketing. During his career at Hoechst he worked across numerous therapeutic areas, including CNS, cardiovascular, and gastrointestinal. Proehl serves on the Board of Directors of Tenax Therapeutics, a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for critical care patients. Proehl is also on the Board of Directors of Auspex Pharmaceuticals, Inc., a pre-NDA biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases. He also serves on the Board of Directors of Sophiris Bio Inc., a publicly traded company developing a late-stage, targeted treatment for benign prostatic hyperplasia. Mr. Proehl also serves on a number of private company boards including Kinetek Sports, Patara Pharma LLC, MDRejuvena, Inc. and Dermata Therapeutics, LLC. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst College.

Paul V. Maier -- Director, Chairman of Audit Committee and Member of Compensation Committee

Paul V. Maier has over 25 years of experience as a senior executive in biotechnology and pharmaceutical companies. From November 2009 through June 2014, Maier served as the Chief Financial Officer of Sequenom Inc., a publicly held company serving the discovery, clinical research, and diagnostics market. From February 2007 until November 2009, he served as an independent financial consultant. Maier was Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals Inc., a commercial stage biopharmaceutical company, a position he held from 1992 through 2007. From 1990 to 1992, Maier served as Vice President, Finance of DFS West, a division of DFS Group LP, a private multinational retailer. From 1984 to 1990, Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly held subsidiary. He serves on the Board of Directors of International Stem Cell Corporation, Apricus Biosciences, MabVax Therapeutics, and Biological Dynamics. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.

Thomas J. Adamek -- Board Observer

Thomas Adamek is a co-founding member, president, and managing director of Stonehenge Capital Company LLC, where he is responsible for asset management and business development activities. He is also a member of its board of managers. Stonehenge is a national specialty finance company with expertise in structured tax credit finance in a variety of industries. Additionally, Stonehenge provides private debt and equity solutions to growing companies. Mr. Adamek received his bachelor’s in finance from LSU in 1982. He began his professional career with Louisiana National Bank, which was the predecessor of Bank One Corporation. From 1983 through 1999, Mr. Adamek held various positions with Bank One, culminating in a managing director role that focused on venture capital, investment banking, and capital markets activities. In 1999, Mr. Adamek co-founded Stonehenge, which today has 35 employees in nine states with partner level oversight in Louisiana and Ohio. Mr. Adamek holds a bachelor’s degree in finance from LSU.

Daniel A. Nathanson -- Board Observer

Dr. Dan Nathanson is an entrepreneur, executive, investor, consultant and educator. He has a 25-year record of success in building businesses, creating financial value and helping entrepreneurs succeed. He is a Visiting Assistant Professor at the UCLA Anderson School of Management where he teaches Small Business Management, Business Plan Development and is a Faculty Advisor in the AMR, GAP and SMR programs. In 1999, Dr. Nathanson founded and serves as CEO of Washington Square Capital Fund (WSCF), a formalized angel group that invests in early-stage companies. In 2000, Dr. Nathanson left the Stern School to become the CEO at Tickmark Solutions. In less than 18 months, under Dr Nathanson’s leadership, the revenues of this software company rose from $500,000 to almost $4 million. In 2002, he engineered the sale of company and investors realized a 40% return on investment in a very difficult market environment. Dr. Nathanson then

LSA Page 10 of 26 © Life Science Analytics, Inc.2019

went on to serve as the CEO and President of a promotional products firm followed by an asset management venture. At these companies, Dr. Nathanson successfully directed the organizations’ growth and worked with the companies’ founders to develop strategies, build infrastructures, create business plans, raise capital, attract investors and establish important strategic relationships. In 2008, Dr. Nathanson accepted a teaching position as a Visiting Assistant Professor at the UCLA Anderson School of Management and has resumed his mission of Helping Entrepreneurs Succeed as the CEO of the Entrepreneurs Resource Group. Dr. Nathanson holds a Ph.D. from the Wharton School of the University of Pennsylvania, an MBA from NYU’s Graduate School of Business and a BA from Washington University in St. Louis, MO.

Michael D. Step -- Director

Michael D. Step was the Senior Vice President of Corporate Development for Santarus, Inc., now a wholly owned subsidiary of Salix Pharmaceuticals, Inc. Step served in this role for nine years up until the 2014 sale of Santarus to Salix. He was responsible for leading all licensing and M&A activities at Santarus and was a member of its executive team. Step held various commercial and business development roles at Amylin Pharmaceuticals for 5 years, culminating in the role of Vice President of Corporate Development and was responsible for leading Amylin’s license of Byetta to Eli Lilly. Before joining Amylin, he was Sr. Director of Business Development at Dura Pharmaceuticals and served in licensing, management and sales roles at Hoffmann-La Roche and Syntex Labs. Step has an MBA degree in marketing and finance from the USC Marshall School of Business and an undergraduate degree from Vanderbilt University.

Robin Schmidt -- Director, Clinical Operations

Robin Schmidt has over 23 years of experience in clinical operations strategy and execution of clinical trials in a diverse range of environments including large-scale pharmaceutical, biotechnology and contract research organizations (CRO). Before joining Ritter, Robin spent four years at Inventiv Health (now Syneos) as global project lead, overseeing a team of regional project managers for a large-scale Phase 3 global trial in immunology. She also led development and implementation of risk evaluation and mitigation plans, and drove innovation and efficiencies across multiple initiatives within the organization. From 2007-2013, Robin served as the clinical operations lead at several biotech companies, including Metabasis Therapeutics, Cerenis Therapeutics and Aastrom Biosciences, where she was responsible for development of company SOPs related to clinical conduct, and also led outsourcing strategy and project delivery for Phase I- III clinical programs across cardiovascular and endocrinology indications. From 1995-2007, Robin served in increasing roles of responsibility at Parke-Davis/Warner-Lambert (acquired by Pfizer in 2001) related to clinical study monitoring and operations management across Phase II-IV global trails in multiple therapeutic areas including CNS, diabetes, gastroenterology, oncology, women’s health, cardiovascular disease, inflammation and pain. Robin holds a Bachelor’s Degree in Biology from the University of Michigan as well as a Master’s Degree in Nutrition Science from the University of Michigan Rackham Graduate School.

Elizabeth Polvent -- Director, Clinical Operations

Elizabeth has over ten years of clinical research experience providing study management duties and monitoring of both nation and internation studies in Phase I-IV. At her previous company, Elizabeth served as a senior clinical program manager of a Phase 1 and Phase 2 study for Gout. In addition she worked as a clinical study manager for a Phase 1 Oncology study. Her experience in clinical trials covers organization, operations, and management. She is also a licensed vocational nurse and has co-authored multiple publications. Elizabeth has a B.S. in General Biology from the University of California at San Diego.

Noah Voreades -- Corporate Development Manager

Marilyn Carlson -- Senior Regulatory Specialist

Marilyn Carlson has over 18 years pharmaceutical industry experience at Synteract, Prometheus Labs, ISTA Pharma, Procter & Gamble and others.

Shaun Novin -- Contact Person

LSA Page 11 of 26 © Life Science Analytics, Inc.2019

Jon Ruckle -- Senior Clinical Scientist

Dr. Ruckle is Board Certified in Internal Medicine and brings extensive clinical practice, teaching, and research experience to Ritter Pharmaceuticals, Inc. He as served as an Investigator for over 280 clinical trials, mostly Phase I, and has worked full time as an Investigator since 1995. He has been Medical Director of 3 Phase I research units. His special interests include Japanese bridging and pan-Asian studies, First-Time-In-Humans studies (including biologics), microdose studies in a variety of special populations including healthy elderly, pediatrics, and patients with osteoporosis, diabetes, obesity, hyperlipidemia, hypertension, asthma, and renal insufficiency. In addition he has consulted with pharmaceutical sponsors and CROs on many aspects of product strategy and protocol development, and served as Medical Monitor on Data Safety Review Boards. He is an alumnus of the Loma Linda University School of Medicine in Loma Linda, CA, with residency training at the Mayo Clinic in Rochester, MN.

Dennis Savaiano -- Chairman, Medical Advisory Board Member

Dennis Savaiano has researched lactose intolerance for the past 20 years, where he has attempted to identify the dietary factors that can improve lactose tolerance. He served as the associate dean and assistant directorr of the Agricultural Experiment Station Human Ecology at the University of Minnesota. Savaiano is a native Californian with degrees from Claremont McKenna College (BA in Biology) and the University of California at Davis (MS and PhD in Nutrition). He was a Professor in the Department of Food Science and Nutrition at the University of Minnesota from 1980 through 1995, and moved to Purdue University in 1995.

W. Allan Walker -- Medical Advisory Board Member

W. Allan Walker has a longstanding interest and commitment to nutrition research, particularly on the role of nutritional factors in maintaining the integrity of the intestinal mucosal barrier to host defense during the perinatal period. He was the first recipient of the Conrad Taff Professorship in Nutrition at Harvard Medical School in 1990. Walker served for six years on the Committee of Nutrition of the American Academy of Pediatrics (1977-1983) and received the Nutrition Research Award (Borden Award) of the American Academy of Pediatrics in 1984 and the Hugh Butt Award for Excellence in Clinical Nutrition Research from the American Gastroenterologic Association in 1998. He has also served on Nutrition study sections at the NICHD and NIDDK institutes and the Advisory Council of NIDDK at NIH and served as a member of the task force to establish a five-year nutrition research plan at NICHD. Walker is the author of 12 textbooks and over 500 research and review articles.

Harry Greene -- Medical Advisory Board Member

Roger Clemens -- Medical Advisory Board Member

Todd Klaenhammer -- Medical Advisory Board Member

Todd R. Klaenhammer obtained degrees in Microbiology (B.S), and Food Science (M.S. & Ph.D) from the University of Minnesota. In 1978, he joined the North Carolina State University and holds faculty appointments in the Departments of Food, Bioprocessing and Nutrition Sciences; and in the Departments of Microbiology and Genetics. His group has published over 270 articles on dairy lactic acid bacteria, their bacteriophages, and probiotic cultures and their genomic traits. Todd is Fellow in the American Association for the Advancement of Science, the American Academy of Microbiology, the Institute of Food Technologists, and the American Dairy Science Association. In 2001, he was elected into the National Academy of Sciences. In 2009, the Board of Governors of the 17 Campus University of North Carolina System, awarded his group the prestigious O. Max Gardner award for excellence in research across the entire system. In 2010, the International Dairy Federation awarded his group the 2010 Eli Metchnikoff Award in Biotechnology and in 2015, the Japan Bifidus Foundation awarded Todd the Tissier Medal for work on probiotic lactic acid bacteria.

Chris Landon -- Medical Advisory Board Member

LSA Page 12 of 26 © Life Science Analytics, Inc.2019

Chris Landon has pioneered device development in the area of pediatric pulmonary medicine. He established a CCS certified Level II Intensive Care Nursery and Perinatal Unit at Sequoia District Hospital and a comprehensive program of inpatient and outpatient medical homes for children in Ventura County. Additionally, he established a program of nutritional research in cystic fibrosis at Children’s Hospital at Stanford, including a microsample lab for fat-soluble vitamins and gas chromatography lab for essential fatty acids. Dr. Landon has served on a variety of medical and scientific advisory boards including the Pediatric Advisory Committee, the American Medical Association, the American Federation of Clinical Research and the California Medical Association. He received his medical degree from the University of Southern California and completed his fellowship at Stanford University.

John L. Sherman -- Medical Advisory Board Member

Dr. John L. Sherman has been a staff physician at Cedars Sinai Medical Center since 1991 and serves as a member of the Medical Education Committee. He was a member of the Risk Management Committee from 1994-2004. Dr. Sherman has been a faculty instructor at UCLA in both Pathophysiology of Respiratory Disease and Fundamentals of Clinical Medicine. He is an Associate Clinical Professor of Medicine at UCLA. Dr. Sherman was Resident of the Year for UCLA Department of Medicine in 1976. He was a Fellow at the American College of Chest Physicians in 1981 and in 1986 was a Fellow at the American College of Physicians.

Warren Grundfest -- Medical Advisory Board Member

William J. Sanborn -- Medical Advisory Board Member

William J. Sanborn serves as the Chief, Division of Gastroenterology and Director at University of California San Diego Inflammatory Bowel Disease Center and Professor of Clinical Medicine. Sandborn directs a large clinical research unit devoted to the conduct of clinical trials in inflammatory bowel disease, where he supervises a multi-investigator team of physicians, research fellows, nurses, and study coordinators. With his physician collaborators, he evaluates and develops new diagnostic modalities and medical therapies for inflammatory bowel disease. He is internationally recognized for his contributions in the fields of biotechnology therapy, clinical pharmacology, conduct of clinical trials, diagnostic and treatment of pouchitis, epidemiology and natural history, and endoscopic and radiographic imaging techniques. He has published more than 408 articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research includes clinical development and clinical pharmacology related to inflammatory bowel disease. From April 1993 to December 2010, Sandborn was head of the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN and from January 2011 to present, the Division of Gastroenterology, University of California San Diego, La Jolla. Sandborn is extremely well regarded and well known within the investment community and is considered one of the key leading gastroenterologists in the United States for pharmaceutical research and clinical trial work.

Byron L. Cryer -- Medical Advisory Board Member

Byron L. Cryer, MD, obtained his BA degree from Harvard College, Cambridge, MA, in 1982, and his medical degree from Baylor College of Medicine, Houston, TX, in 1986, where he also completed his internal medicine residency training from 1986 to 1989. Cryer obtained his gastroenterology fellowship training at The University of Texas Southwestern Medical Center at Dallas (1989-92), where he has remained as a member of the gastroenterology faculty. Cryer's clinical interests are in general gastroenterology. His specific areas of interest are acid- peptic diseases of the upper gastrointestinal tract. Specific disease states of interest are Helicobacter pylori-induced ulcer disease and nonsteroidal anti-inflammatory drug-induced ulcers. Cryer’s primary research interest has been in the pathogenesis of peptic ulcer disease. His research focus has been clinically oriented in that he has exclusively studied the pathophysiology of these processes in humans. Investigations have explored the mechanism of gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) within the stomach and duodenum. The aspect of NSAID investigation has been an evaluation of the cyclooxygenase (COX)-2 specific NSAIDs. Within the AGA, Cryer has held many leadership positions. He is the past chair of the AGA Underrepresented Minorities Committee and a AGA International Committee, AGA Institute Research Policy Committee, and AGA Institute Education and Training Committee. He has also led several AGA- sponsored public awareness campaigns to reduce the GI risks of NSAIDs and other commonly taken pain medications. Cryer holds the position of councillor-at-large on the AGA Institute Governing board..

LSA Page 13 of 26 © Life Science Analytics, Inc.2019

William Chey -- Medical Advisory Board Member

William Chey is Nostrant Collegiate Professor of Gastroenterology & Nutrition Sciences, Director of the GI Physiology Laboratory, and Co- Director of the Michigan Bowel Control Program at Michigan Medicine. He also serves as a member of the Board of Trustees of the American College of Gastroenterology, the Board of Directors of the Rome Foundation and a member of the Advisory Board of the International Foundation of Functional GI Disorders. Dr. Chey has authored more than 300 manuscripts, reviews and book chapters, and he was the Co-Editor-in-Chief of the American Journal of Gastroenterology from 2010 to 2015. He has been elected to “Best Doctors” since 2001 and “America’s Top Doctors” since 2009. Dr. Chey has been inducted into the Clinical Excellence Society of the Department of Medicine, received the Dean’s Outstanding Clinician Award, was inducted into the League of Research Excellence at the University of Michigan and has received the Distinguished Clinician Award from the American Gastroenterological Association. Dr. Chey received his B.A. from the University of Pennsylvania and medical degree and training in internal medicine at the Emory University School of Medicine, completing his fellowship in gastroenterology at the University of Michigan.

Randy Whitcomb -- Clinical and Strategic Advisor

Dr. Whitcomb was a Founder and Senior Clincal Research Fellow at QuatRx Pharmaceuticals from 2000-2006 and serves as a consultant to multiple biotechnology companies. Formerly, he served in various management positions at Parke-Davis, the pharmaceutical division of Warner-Lambert, including Vice President for Clinical Research and Drug Development. Prior to his tenure at Parke-Davis, he was on the faculty of the Harvard Medical School and an attending physician at Massachusetts General Hospital. Dr. Whitcomb has authored multiple scientific publications and is a member of numerious scientific and clinical organizations. He serves on the Board of Directors of Insmed, Incorporated.

Dick Johnson -- Team Member - Product Development & Manufacturing

Dick founded RG Johnson Pharmaceutical Consulting which focuses on Active Pharmaceutical Ingredient and finished dosage form production. He specializes in the areas of small molecule development and production, aseptic and sterile product production, and clinical global supply. Before founding his own company, Dick worked for Avera Pharmaceutical as the Vice President of Manufacturing where he was responsible for the development and manufacture of three acquired drug products from GSK, Lilly, and Novartis. He also successfully produced GMP drug substance and drug products approved by US and EU regulatory authorities for Phase 1 and 2 clinical trials. Dick’s 40 year history in manufacturing also includes Vice President of Imaging Operations at the Mallinckrodt Imaging Division of Tyco Healthcare. Dick received a BS in Chemical Engineering at the University of South Carolina and an MBA from East Carolina University.

Eric Gruff -- Team Member - Product Development & Manufacturing

Dr. Gruff founded E4 Consulting, which specializes in providing pharmaceutical consulting services to biotechnology and pharmaceutical clients. He has over 19 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals, and Molecular Biosystems. More specifically, Dr. Gruff has expertise in Chemistry, Manufacturing, and Controls (CMC), Product Development, and Regulatory Affairs. Dr. Gruff’s history includes 11 years with Pfizer’s La Jolla Laboratories in a variety of leadership roles in Pharmaceutical Development and Project Management. Prior to joining Pfizer, he held management positions at Molecular Biosystems, Inc. He has also served as an independent regulatory consultant with responsibility for creating submissions for several new drug and biologic candidates, and medical devices.

Alene Campbell -- Team Member - Operations & Corporate Development

Ms. Campbell brings over 30 years of experience to Ritter Pharma, having held executive positions in the biotechnology, diagnostic, and pharmaceutical industries. In addition to being part of the Ritter Pharma team, Ms. Campbell is a senior partner for BioVirtue LLC, a company that provides executive and consulting services for the medical community. Prior to her work with BioVirtue, Ms. Campbell served as C.E.O. and C.O.O. at MicroPhage, a bacterial diagnostics firm, where she directed finance, research and development, product development, human resources, and clinical affairs. She has held other significant positions in the industry, including VP of Corporate Development at Myogen (now Gilead), General Manager of RPI/SiRNA (now Merck), Executive VP of ChemTrak, and VP of Hana Biologics. Ms. Campbell holds an MBA from the University of California, Berkeley.

Howard Foyt -- Management Team Member, Clinical Development

LSA Page 14 of 26 © Life Science Analytics, Inc.2019

Dr. Foyt oversees Ritter’s clinical development efforts as well as assists in building the Company’s overall infrastructure and management team. He brings extensive clinical and leadership experience to Ritter Pharma having spent the last seventeen years at major pharmaceutical companies. Prior to Ritter Pharma, Dr. Foyt served as Senior Vice President and Chief Medical Officer at Cebix, Inc. He previously was Vice President, Clinical Development at Metabasis Therapeutics, which he joined from Pfizer Global Research & Development where he served as Senior Director, Medical & Development Sciences and Therapy Area Site Head—Diabetes & Obesity. He began his industry career over fifteen years ago at Parke-Davis Pharmaceutical Research, Ann Arbor, MI where he was Director, Clinical Research, Endocrine and Metabolism prior to the acquisition of the company by Pfizer. He earned his medical degree in 1985 from Baylor College of Medicine where he also earned a Ph.D. in Cell Biology. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

Justin Chandler -- Contact Person, Media Relations

Susan Rogers -- Contact Person

David Burke -- Contact Person - Investor and Media Relations

LSA Page 15 of 26 © Life Science Analytics, Inc.2019

Recent News Company Announcemets

06/28/2018 -- Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer

On June 27, 2018 Ritter Pharmaceuticals, Inc announced that Andrew J. Ritter has been appointed to the position of CEO, effective June 27, 2018, succeeding Michael D. Step, who will remain on the Company’s board of directors and serve as a consultant to the company.

05/30/2018 -- Ritter Pharmaceuticals Announces Appointment of John W. Beck as Chief Financial Officer

On May 29, 2018 Ritter Pharmaceuticals, Inc announced that it has appointed John W. Beck as chief financial officer.

03/23/2018 -- Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split

On March 22, 2018 Ritter Pharmaceuticals announced a 1-for-10 reverse split of its Common Stock, par value $0.001 per share (the “Common Stock”), effective tomorrow, March 23, 2018 (the “Effective Date”). The reverse stock split was approved by the Company’s stockholders at a special meeting of stockholders held on December 20, 2017. The specific 1-for-10 ratio was subsequently announced by the Company’s Board of Directors on March 1, 2018. The Company has filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of the State of Delaware to effect the reverse stock split.

02/21/2018 -- Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, M.D., to Medical Advisory Board

On February 20, 2018 Ritter Pharmaceuticals, Inc. announced the appointment of William Chey, M.D., to its Medical Advisory Board.

01/30/2018 -- Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase III Clinical Trial

On January 29, 2018 Ritter Pharmaceuticals, Inc announced the appointment of Diane J. Plotkin, Ph.D., as Vice President of Clinical Development.

01/31/2017 -- Ritter Pharmaceuticals to Ring Today’s Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month

On January 30, 2017 Ritter Pharmaceuticals, Inc. will be ringing the closing bell for the Nasdaq stock market in New York today, Monday, January 30, 2017 at 4:00 p.m. EST to kick-off Lactose Intolerance Awareness Month.

01/31/2017 -- Ritter Pharmaceuticals to Ring Today’s Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month

On January 30, 2017 Ritter Pharmaceuticals, Inc announced that it will be ringing the closing bell for the Nasdaq stock market in New York on January 30, 2017 at 4:00 p.m. EST to kick-off Lactose Intolerance Awareness Month.

01/18/2017 -- Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors

On January 17, 2017 Ritter Pharmaceuticals, Inc. announced that it has appointed William Merino, Ph.D., to its Board of Directors. Dr. Merino will occupy a newly-created seat, advising on regulatory, clinical and related strategies.

10/22/2015 -- Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board

On October 21, 2015 Ritter Pharmaceuticals, Inc. announced the appointment of William J. Sandborn, M.D. to its Medical Advisory Board.

10/07/2015 -- Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer

On October 6, 2015 Ritter Pharmaceuticals, Inc. announced the appointment of AnnKatrin Petersen-Jappelli, M.D., M.Sc. as its Chief Medical Officer.

LSA Page 16 of 26 © Life Science Analytics, Inc.2019

08/06/2015 -- Ritter Pharmaceuticals Retains William M. Merino as Senior Clinical and Regulatory Advisor

On August 5, 2015 Ritter Pharmaceuticals announced that William (Bill) Merino has been retained as a senior clinical and regulatory advisor to the company.

04/23/2015 -- Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors

On April 22, 2015 Ritter Pharmaceuticals, Inc announced that Gerald T. Proehl has joined the Company’s Board of Directors. With his appointment, the Ritter Pharma Board now has seven Directors. Mr. Proehl will chair the Company’s nominating and corporate governance committee.

04/15/2015 -- Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors

On April 14, 2015 Ritter Pharmaceuticals, Inc announced the appointment of Paul V. Maier to the Company’s Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company’s audit committee.

02/10/2015 -- Ritter Pharmaceuticals Names Matthew W. Foehr to its Board of Directors

On February 9, 2015 Ritter Pharmaceuticals, Inc. announced the appointment of Matthew W. Foehr to the Company’s Board of Directors. Mr. Foehr is President and Chief Operating Officer of Ligand Pharmaceuticals and his appointment expands Ritter’s Board membership to 5 Directors.

10/01/2014 -- Ritter Pharmaceuticals Names Michael D. Step Chief Executive Officer

On September 30, 2014 Ritter Pharmaceuticals, Inc., announced that Michael D. Step has been named chief executive officer, effective October 1, 2014. Mr. Step was appointed to the company’s board of directors in 2011 and will continue to serve as a director.

LSA Page 17 of 26 © Life Science Analytics, Inc.2019

Deals and Alliances

05/04/2018 -- Ritter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase III Clinical Trial of RP-G28 in Lactose Intolerance

On May 3, 2018 Ritter Pharmaceuticals Inc announced that it has signed an agreement with the clinical research organization (CRO) Medpace to conduct the first of two pivotal Phase III clinical trials for RP-G28 in patients with lactose intolerance (LI).

02/14/2017 -- Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy

On February 13, 2017 Ritter Pharmaceuticals, Inc announced that it is collaborating with Dr. B Brett Finlay from the Michael Smith Laboratories at the University of British Columbia (“UBC”) to study the role of the microbiome and RP-G28 in environmental enteropathy (“EE”).

01/24/2017 -- Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome

On January 23, 2017 Ritter Pharmaceuticals, Inc announced that it is collaborating with the newly-established Food for Health Center at the University of Nebraska to study the role of the microbiome and RP-G28 in metabolic syndrome.

LSA Page 18 of 26 © Life Science Analytics, Inc.2019

Financials

11/07/2018 -- Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred

On November 6, 2018 Ritter Pharmaceuticals, Inc announced the closing on November 5, 2018 of its previously announced private placement of Series B convertible preferred stock and warrants to certain accredited investors, including two current institutional holders of our Series A convertible preferred stock, a key vendor and a member of the Company’s board of directors. The Company received gross proceeds of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

11/01/2018 -- Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

On October 31, 2018 Ritter Pharmaceuticals, Inc announced that it has entered into a definitive agreement with certain accredited investors, including two current institutional holders of our Series A convertible preferred stock, a key vendor and a member of the Company’s board of directors, for a private placement of newly designated Series B convertible preferred stock and warrants.

11/01/2017 -- Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

On October 31, 2017 Ritter Pharmaceuticals, Inc. reported financial results and a business update for the third quarter ended September 30, 2017.

10/04/2017 -- Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase III Clinical Program in Lactose Intolerance

On October 3, 2017 Ritter Pharmaceuticals, Inc announced the closing of its previously announced underwritten public offering with total gross proceeds to the Company of approximately $23 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

09/30/2017 -- Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering

On September 29, 2017 Ritter Pharmaceuticals, Inc announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $23,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

11/08/2016 -- Ritter Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update

On November 7, 2016 Ritter Pharmaceuticals Inc reported financial results and a business update for the third quarter ending September 30, 2016.

10/27/2016 -- Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering of Common Stock

On October 26, 2016 Ritter Pharmaceuticals Inc announced the pricing of an underwritten public offering of 2,127,660 shares of its common stock at a price to the public of $2.35. The gross proceeds to Ritter Pharmaceuticals, Inc. from this offering are expected to be approximately $5,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Ritter Pharmaceuticals, Inc. has granted the underwriters a 30-day option to purchase up to an additional 319,149 shares of common stock to cover over-allotments, if any. The offering is expected to close on October 31, 2016, subject to customary closing conditions.

10/26/2016 -- Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

On October 25, 2016 Ritter Pharmaceuticals, Inc announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from this offering for working capital and to fund other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

08/09/2016 -- Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

On August 8, 2016 Ritter Pharmaceuticals, Inc reported financial results and a business update for the second quarter ended June 30, 2016.

03/22/2016 -- Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update

On March 21, 2016 Ritter Pharmaceuticals, Inc. has reported financial results and a business update for the fourth quarter and full year ended December 31, 2015.

12/22/2015 -- Ritter Pharmaceuticals Enters Into a $10 Million Common Stock Purchase Agreement with Aspire Capital Fund

On December 21, 2015 Ritter Pharmaceuticals, Inc. announced that it has entered into a $10 million common stock purchase agreement (the “Purchase Agreement”) and a registration rights agreement with Aspire Capital Fund, LLC (“Aspire”), a Chicago-based institutional investor.

11/18/2015 -- Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update

On November 17, 2015 Ritter Pharmaceuticals, Inc. reported financial results and a business update for the third quarter ended September 30, 2015.

06/30/2015 -- Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering

On June 29, 2015 Ritter Pharmaceuticals, Inc. announced the closing of its previously announced initial public offering of 4,000,000 shares of its common stock at a price to the public of $5.00 per share.

Intellectual Property

05/03/2017 -- Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase III

On May 2, 2017 Ritter Pharmaceuticals announced that it has been issued three new patents directed to its development compound RP- G28. The Company is also providing an update on its Phase III program based on conversations with regulatory authorities and experts.

06/29/2016 -- Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28

On June 28, 2016 Ritter Pharmaceuticals, Inc. announced that it recently has been issued U.S. Patent No. 9,370,532 by the U.S. Patent & Trademark Office.

02/17/2016 -- Ritter Pharmaceuticals Issued Two New Patents

On February 16, 2016 Ritter Pharmaceuticals, Inc. announced that it recently has been issued U.S. Patent Nos. 9,200,303 and 9,226,933 by the U.S. Patent & Trademark Office.

Product Updates

05/08/2019 -- Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase III Clinical Trial of RP-G28 in Patients with Lactose Intolerance

On May 7, 2019 Ritter Pharmaceuticals, Inc announced that the final patient in its first pivotal Phase III clinical trial of RP-G28 for the potential treatment of Lactose intolerance (LI), a study known as the “Liberatus” study (NCT03597516), has completed the 30-day treatment dosing period.

03/06/2019 -- Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase III Clinical Trial of RP-G28 in Patients with Lactose Intolerance

On March 5, 2019 Ritter Pharmaceuticals announced that it has completed, ahead of schedule, enrollment in its first pivotal Phase III clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study (NCT03597516).

03/01/2019 -- Dr. William Chey Highlights Unmet Medical Need of Lactose Intolerance and Potential for Phase III Drug Candidate RP-G28 in Expert Call Hosted by Ritter Pharmaceuticals

On February 28, 2019 Ritter Pharmaceuticals, Inc recaps remarks made by Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan in an expert call hosted by the Company.

12/05/2018 -- Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase III Clinical Trial of RP-G28 in Patients with Lactose Intolerance

On December 4, 2018 Ritter Pharmaceuticals, Inc announced that it has passed the 50 percent enrollment point in its first pivotal Phase III clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study.

11/01/2018 -- Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

10/10/2018 -- Ritter Pharmaceuticals Presents Additional Phase IIb Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting

On October 9, 2018 Ritter Pharmaceuticals, Inc presented additional data from its previously completed Phase IIb trial of RP-G28 exhibiting colonic microbiome adaptation and improved lactose tolerance.

06/28/2018 -- Ritter Pharmaceuticals Initiates First Pivotal Phase III Trial for RP-G28 for the Treatment of Lactose Intolerance

On June 27, 2018 Ritter Pharmaceuticals, Inc. announced that the first patient has been enrolled in the first pivotal Phase III clinical trial of RP- G28.

06/06/2018 -- Ritter Pharmaceuticals Highlights Key Phase IIb Clinical Trial Data of RP-G28 for Lactose Intolerance at Digestive Disease Week 2018

On June 5, 2018 Ritter Pharmaceuticals Inc announced that they presented highlighted data and additional insights from its previously completed Phase IIb trial of RP-G28 in two posters at Digestive Disease Week, 2018 in Washington, D.C.

05/23/2018 -- Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP- G28 for Lactose Intolerance

On May 22, 2018 Ritter Pharmaceuticals, Inc announced that it will be presenting two posters of additional data from the Phase IIb trial of RP- G28 at Digestive Disease Week, June 2-5, 2018 in Washington, D.C.

03/13/2018 -- Ritter Pharmaceuticals Reports Microbiome Data from Phase IIb Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome

On March 12, 2018 Ritter Pharmaceuticals, Inc. announced that its lead drug, RP-G28, promoted beneficial adaptation of the gut microbiome in its Phase IIb study of 377 lactose intolerance patients.

11/03/2017 -- Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress

On November 2, 2017 Ritter Pharmaceuticals, Inc announced that the Company’s Chief Executive Officer, Michael Step, will present at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress on November 3, 2017, in San Diego. Mr. Step presentation is entitled: “Pioneering Development in the Gut Microbiome for the Treatment of Lactose Intolerance.”

10/04/2017 -- Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase III Clinical Program in Lactose Intolerance

08/19/2017 -- Ritter Pharmaceuticals Announces Phase III Plans after its End of Phase II Meeting with FDA on RP-G28 for Lactose Intolerance

On August 18, 2017 Ritter Pharmaceuticals, Inc announced its Phase III plans following its End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) regarding the path forward for RP-G28 for the treatment of lactose intolerance (LI).

08/04/2017 -- Ritter Pharmaceuticals Reports Further Analysis from its Phase IIb/III Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms

On August 3, 2017 Ritter Pharmaceuticals, Inc. announced additional findings and data analysis from its Phase IIb/III study designed to evaluate lead candidate RP-G28 in subjects with lactose intolerance.

05/03/2017 -- Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase III

04/13/2017 -- Ritter Pharmaceuticals, Inc. Announces End of Phase II Meeting with the FDA and Initiates Phase III Program Development Activities

On April 12, 2017 Ritter Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has agreed to schedule an end of Phase II meeting with the company which is expected to take place in the third quarter of 2017. The Company plans to discuss the results of its recently completed Phase IIb/III trial and Phase III plans in preparation of a New Drug Application (NDA) submission of RP-G28 for the treatment of lactose intolerance. The completed Phase IIb/III trial demonstrated several positive topline results and full analysis of the data is underway. The trial was the largest well-controlled clinical study ever conducted in lactose intolerance.

03/29/2017 -- Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase IIb/III Clinical Trial

On March 28, 2017 Ritter Pharmaceuticals, Inc. announced topline findings from its Phase IIb/III study designed to evaluate RP-G28 in subjects with lactose intolerance. Results from the 377-subject trial show a clinically meaningful benefit to subjects in the reduction of lactose intolerance symptoms across a variety of outcome measures. The majority of analyses showed positive outcome measures and the

robustness of the data point to a clear drug effect. Based on these trial results, the Company believes that the successful completion of a confirmatory Phase III program could be adequate to support a New Drug Application (NDA) submission and therefore has requested an end-of-Phase II meeting with the U.S. Food and Drug Administration (FDA).

01/31/2017 -- Ritter Pharmaceuticals to Ring Today’s Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month

01/04/2017 -- Ritter Pharmaceuticals Phase IIa Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences

On January 3, 2017 Ritter Pharmaceuticals, Inc announced that clinical microbiome data from its Phase IIa clinical trial of RP-G28 in patients with lactose intolerance were published in the Proceedings of the National Academy of Science (“PNAS-Plus”) PNAS 2017; Early Edition, published ahead of print January 3, 2017.

10/18/2016 -- Ritter Pharmaceuticals Concludes Last Patient Visit of its Phase IIb/III Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance

On October 17, 2016 Ritter Pharmaceuticals, Inc announced that the last patient has completed dosing and all monitoring visits in its Phase IIb/III clinical trial of RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017.

10/06/2016 -- Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum

On October 5, 2016 Ritter Pharmaceuticals Inc announced that the Company’s Chief Executive Officer, Michael Step, presented at the 4th Microbiome R&D Business Collaboration Forum & Panel on October 4, 2016 in San Diego, CA.

08/16/2016 -- Ritter Pharmaceuticals Completes Enrollment for Phase IIb/III Trial of RP-G28 in Lactose Intolerance

On August 15, 2016 Ritter Pharmaceuticals, Inc announced that it has completed patient enrollment on schedule for its Phase IIb/III clinical trial of its investigational compound RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017.

03/22/2016 -- Ritter Pharmaceuticals Doses First Patient in Phase IIb/III Trial of RP-G28 in Lactose Intolerance

On March 21, 2016 Ritter Pharmaceuticals, Inc. announced the dosing of the first patient in its Phase IIb/III clinical trial of RP-G28 for the treatment of lactose intolerance.

03/15/2016 -- Ritter Pharmaceuticals Initiates Phase IIB/III Clinical Trial of RP-G28 in Lactose Intolerance

On March 14, 2016 Ritter Pharmaceuticals, Inc. announced initiation of its Phase II B/III clinical trial of RP-G28, which has the potential to be the first FDA-approved treatment for lactose intolerance.

12/22/2015 -- Ritter Pharmaceuticals Enters Into a $10 Million Common Stock Purchase Agreement with Aspire Capital Fund

09/09/2015 -- Ritter Pharmaceuticals to Present at the 3rd Microbiome R&D Business Collaboration Forum

On September 8, 2015 Ritter Pharmaceuticals, Inc. announced that the Company’s Chief Executive Officer, Michael Step, will participate in the 3rd Microbiome R&D Business Collaboration Forum to be held September 10-11, 2015 in San Diego, CA.

01/09/2014 -- Ritter Pharmaceuticals Announces Publication of Lactose Intolerance Phase II Trial in Nutrition Journal

On January 8, 2014 Ritter Pharmaceuticals, Inc announced that Nutrition Journal has published the results of its Phase II trial of RP-G28, a proprietary oligosaccharide under investigation as a potential treatment for lactose intolerance. The study manuscript entitled, “Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial” is the first peer-reviewed presentation of the protocol, assessments and results which showed that RP-G28 dramatically reduced the pain and symptoms of lactose intolerant patients.

Regulatory

04/13/2017 -- Ritter Pharmaceuticals, Inc. Announces End of Phase II Meeting with the FDA and Initiates Phase III Program Development Activities

Although Informa UK Ltd will endeavor to keep the Publications and/or Content updated and accurate, the Publications and/or Content are voluminous and often change. Accordingly, (a) Informa UK Ltd cannot and does not warrant the accuracy or completeness of the Publications and/or Content and (b) Informa UK Ltd will not be liable for any adverse consequences arising as a result of the inaccuracy or incompleteness of the Publications and/or Content. Informa UK Ltd will not be liable for any trading, investment or commercial decisions made in reliance on the Publications and/or Content. Informa UK Ltd is the sole source and proprietor of the Publication and will not be liable for adverse consequences or trading, investment or commercial decisions.